Geovax announces license agreement with nih to support covid-19 vaccine development

Atlanta, ga, oct. 26, 2020 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaqcm: govx, govxw) (“geovax” or the “company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced the signing of a patent and biological materials license agreement (the “license agreement”) with the national institute of allergy and infectious diseases (niaid), part of the national institutes of health (nih), in support of geovax's development of a vaccine against sars-cov-2,  the virus that causes covid-19. the patent license agreement to geovax includes access to niaid's patent rights in the stabilized spike protein, which is the protein that sars-cov-2 uses to gain entry into human tissue. 
GOVX Ratings Summary
GOVX Quant Ranking